Remdesivir, hailed as potential COVID-19 treatment, gets emergency U.S. FDA green light

Remdesivir has received emergency use authorization (EUA) from the U.S. Food and Drug Administration after a major study showed that it can reduce recovery time for hospitalized COVID-19 patients.

In a news release on Friday, the FDA said it has issued the EUA for “treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease.”

The FDA acknowledged there is “limited information” so far about how effective or safe the drug is.

U.S. Health and Human Services Secretary Alex Azar hailed the FDA announcement as a “significant step” in the efforts to find a treatment for COVID-19, which so far has no approved treatment or vaccine.

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

An emergency use authorization by the FDA is not the same as drug approval.

More to come.

Source: Read Full Article

Related posts:
  1. Staff member tests positive for coronavirus at Langley care home
  2. UBC medical students organize PPE donations to help front-line workers fight COVID-19
  3. Mobile unit set up to help treat COVID-19 patients from B.C.’s Mission Institution
  4. Coronavirus confirmed at B.C. women’s prison
  5. Colorado’s coronavirus death count to grow by 130 this week as old deaths are added